Notably, neither food intake nor gene expression patterns associated with the appetite-regulating peptides (ghrelin, peptide YY, and glucagon-like peptide-1) exhibited differences between mice with and without NAFLD phenotypes on HFD in all the animal trials (Fig. S2L to N and S9L and M). This evidence concerns the gene GHRL and metabolic dysfunction-associated steatotic liver disease.